Evidence map›Paper›PMID 40067044›Full record

ArticleAntimicrobial agents and chemotherapy2025

Amikacin dosing in neonates: evaluation of target attainment using a simplified and complex pharmacokinetic model-derived dosing regimen in clinical practice.

Marlotte A A van der Veer, Anne Smits, Timo R de Haan, Linda G W Franken, Anton H van Kaam, Caspar J Hodiamont, Yuma A Bijleveld, Karel Allegaert, Ron A A Mathôt

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marlotte A A van der VeerDepartment of Pharmacy & Clinical Pharmacology, Amsterdam University Medical Center, Amsterdam, The Netherlands.ORCID 0000-0002-2600-1381
Anne SmitsNeonatal Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium.
Timo R de HaanDepartment of Neonatology, Emma Children's Hospital, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Linda G W FrankenDepartment of Pharmacy & Clinical Pharmacology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Anton H van KaamDepartment of Neonatology, Emma Children's Hospital, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Caspar J HodiamontMedical Microbiology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Yuma A BijleveldDepartment of Pharmacy & Clinical Pharmacology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Karel AllegaertNeonatal Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium.
Ron A A MathôtDepartment of Pharmacy & Clinical Pharmacology, Amsterdam University Medical Center, Amsterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amikacin is frequently used for the treatment of neonatal sepsis. The Dutch Pediatric Formulary recommends a complex pharmacokinetic (PK) model-derived dosing regimen, which consists of dosing categories based on postnatal age and weight that results in adequate PK/pharmacodynamic (PK/PD) target attainment. However, a simplified dosing regimen may be easier to apply in clinical practice. We evaluated PK/PD target attainment of amikacin in neonates using this simplified or complex dosing regimen. This retrospective cohort study included neonates with routinely measured amikacin concentrations at the neonatal intensive care units of the Amsterdam University Medical Center (simplified dosing regimen) or University Hospitals Leuven (complex dosing regimen). Peak (C

Indexed as

AmikacinAnti-Bacterial AgentsNeonatal SepsisArea Under CurveBayes TheoremFemaleHumansInfant, NewbornIntensive Care Units, NeonatalMaleMicrobial Sensitivity TestsRetrospective StudiesAmikacinAnti-Bacterial Agentsamikacinantimicrobial therapyneonatespharmacokineticssepsistarget attainment

Identifiers

PMID40067044
PMCPMC11963607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.